HK1219724A1 - 用於預防和/或治療中樞神經系統退行性失調的新穎組合物 - Google Patents

用於預防和/或治療中樞神經系統退行性失調的新穎組合物

Info

Publication number
HK1219724A1
HK1219724A1 HK16107625.0A HK16107625A HK1219724A1 HK 1219724 A1 HK1219724 A1 HK 1219724A1 HK 16107625 A HK16107625 A HK 16107625A HK 1219724 A1 HK1219724 A1 HK 1219724A1
Authority
HK
Hong Kong
Prior art keywords
preventing
nervous system
central nervous
novel compositions
degenerative disorders
Prior art date
Application number
HK16107625.0A
Other languages
English (en)
Inventor
.博伊德
.李
.瑞比克金斯基
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of HK1219724A1 publication Critical patent/HK1219724A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/191Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96Sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
HK16107625.0A 2009-10-19 2013-03-01 用於預防和/或治療中樞神經系統退行性失調的新穎組合物 HK1219724A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25280309P 2009-10-19 2009-10-19

Publications (1)

Publication Number Publication Date
HK1219724A1 true HK1219724A1 (zh) 2017-04-13

Family

ID=43879775

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16107625.0A HK1219724A1 (zh) 2009-10-19 2013-03-01 用於預防和/或治療中樞神經系統退行性失調的新穎組合物

Country Status (27)

Country Link
US (4) US8604206B2 (zh)
EP (2) EP2490532B1 (zh)
JP (2) JP5805649B2 (zh)
KR (3) KR101880411B1 (zh)
CN (2) CN105367485B (zh)
AR (1) AR078606A1 (zh)
AU (3) AU2010308396B2 (zh)
BR (1) BR112012009121A2 (zh)
CA (1) CA2778348C (zh)
CY (1) CY1118966T1 (zh)
DK (1) DK2490532T3 (zh)
ES (2) ES2617192T3 (zh)
HK (1) HK1219724A1 (zh)
HR (1) HRP20170236T1 (zh)
HU (1) HUE033116T2 (zh)
IL (1) IL219160B (zh)
LT (1) LT2490532T (zh)
MX (2) MX340807B (zh)
PL (1) PL2490532T3 (zh)
PT (1) PT2490532T (zh)
RS (1) RS55679B1 (zh)
RU (2) RU2015147509A (zh)
SG (1) SG10201507159XA (zh)
SI (1) SI2490532T1 (zh)
SM (1) SMT201700105B (zh)
TW (1) TWI642434B (zh)
WO (1) WO2011049736A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2617192T3 (es) * 2009-10-19 2017-06-15 Amicus Therapeutics, Inc. Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central
BR112012009123A2 (pt) 2009-10-19 2017-09-19 Amicus Therapeutics Inc novas composições para a prevenção e/ou tratamento de distúrbios de depósito lisossômico
EP2591823A1 (en) * 2011-11-11 2013-05-15 Biologische Heilmittel Heel GmbH Composition for treating or preventing neurodegenerative disorders
US9464050B2 (en) * 2012-03-27 2016-10-11 Amicus Therapeutics, Inc. Compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system
US9796680B2 (en) 2013-12-23 2017-10-24 Alectos Therapeutics Inc. Glucocerebrosidase modulators and uses thereof
US10179128B2 (en) 2015-08-31 2019-01-15 Amicus Therapeutics, Inc. Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system
US11358926B2 (en) 2017-04-25 2022-06-14 Amicus Therapeutics, Inc. Compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders
RU2676956C1 (ru) * 2017-08-25 2019-01-11 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Антитела для связывания имиглюцеразы и их применение в аффинной хроматографии
KR101991276B1 (ko) 2018-01-19 2019-06-21 전남대학교산학협력단 신규 균주 페니실리움 아쿠아티쿰 및 이를 이용한 퇴행성 뇌질환 치료제
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
JP4215273B2 (ja) 1991-04-25 2009-01-28 ブラウン ユニヴァーシティ リサーチ ファンデーション 選択された治療物質放出用の移植可能で生体適合性の免疫遮断性ビークル
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
ATE220327T1 (de) 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
JP4128615B2 (ja) * 1994-03-09 2008-07-30 ノボ ノルディスク アクティーゼルスカブ ピペリジン及びピロリジン
US5863903A (en) * 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US20040082641A1 (en) 2002-10-28 2004-04-29 Rytved Klaus Asger Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
JP2006507359A (ja) * 2002-10-28 2006-03-02 ノボ・ノルデイスク・エー/エス 心循環器疾患の治療のためのグリコーゲンホスホリラーゼ阻害剤の使用
US7446098B2 (en) 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
JP2007516294A (ja) 2003-12-23 2007-06-21 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 炎症性の疾患または症状の予防および治療のための方法および組成物
US7501439B2 (en) 2006-05-24 2009-03-10 Amicus Therapeutics, Inc. Tartrate salt of isofagomine and methods of use
ES2364586T3 (es) * 2006-05-24 2011-09-07 Amicus Therapeutics, Inc. Sal tartrato de isofagomina y métodos de uso.
JP5303458B2 (ja) * 2006-06-23 2013-10-02 アミークス セラピューティックス インコーポレイテッド β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法
EP2150254A4 (en) 2007-04-26 2010-11-10 Amicus Therapeutics Inc DOSAGES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH PHARMACOLOGICAL CHAPTERONES
US20110237538A1 (en) 2008-08-06 2011-09-29 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
CA2758187C (en) * 2009-04-09 2017-03-07 Robert Boyd Methods for preventing and/or treating degenerative disorders of the central nervous system
US8940766B2 (en) 2009-04-09 2015-01-27 Amicus Therapeutics, Inc. Methods for preventing and/or treating lysosomal storage disorders
ES2617192T3 (es) * 2009-10-19 2017-06-15 Amicus Therapeutics, Inc. Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central
BR112012009123A2 (pt) * 2009-10-19 2017-09-19 Amicus Therapeutics Inc novas composições para a prevenção e/ou tratamento de distúrbios de depósito lisossômico
DK2490712T3 (en) * 2009-10-19 2015-10-05 Amicus Therapeutics Inc PROCESS FOR THE TREATMENT OF ALZHEIMER'S DISEASE BY USING Pharmacological chaperones TO INCREASE ACTIVITY OF GANGLIOSIDASER
KR102023720B1 (ko) 2012-09-03 2019-09-20 엘지이노텍 주식회사 보이스 코일 모터

Also Published As

Publication number Publication date
CN102655747A (zh) 2012-09-05
US20110092541A1 (en) 2011-04-21
CA2778348C (en) 2022-08-23
SG10201507159XA (en) 2015-10-29
MX2012004548A (es) 2012-07-04
TWI642434B (zh) 2018-12-01
CA2778348A1 (en) 2011-04-28
RU2581058C2 (ru) 2016-04-10
JP6258245B2 (ja) 2018-01-10
DK2490532T3 (en) 2017-02-27
MX340807B (es) 2016-07-27
EP2490532A1 (en) 2012-08-29
US8604206B2 (en) 2013-12-10
AU2017272296B2 (en) 2019-07-11
AU2010308396B2 (en) 2016-04-28
US20160326114A1 (en) 2016-11-10
JP5805649B2 (ja) 2015-11-04
EP2490532A4 (en) 2013-06-12
IL219160A0 (en) 2012-06-28
KR101769396B1 (ko) 2017-08-18
KR20180001588A (ko) 2018-01-04
KR20170096220A (ko) 2017-08-23
CN105367485B (zh) 2018-04-17
KR20120104549A (ko) 2012-09-21
SMT201700105B (it) 2017-03-08
JP2015157822A (ja) 2015-09-03
LT2490532T (lt) 2017-03-27
KR101880411B1 (ko) 2018-07-19
AU2016203817A1 (en) 2016-06-30
PL2490532T3 (pl) 2017-05-31
PT2490532T (pt) 2017-02-23
US10421724B2 (en) 2019-09-24
IL219160B (en) 2018-12-31
US20140080871A1 (en) 2014-03-20
RU2012120759A (ru) 2013-11-27
HRP20170236T1 (hr) 2017-04-07
JP2013508366A (ja) 2013-03-07
HUE033116T2 (en) 2017-11-28
US9409862B2 (en) 2016-08-09
AR078606A1 (es) 2011-11-23
US20180273474A1 (en) 2018-09-27
CN105367485A (zh) 2016-03-02
WO2011049736A1 (en) 2011-04-28
RS55679B1 (sr) 2017-07-31
ES2617192T3 (es) 2017-06-15
EP3143875B1 (en) 2020-05-27
AU2010308396A1 (en) 2012-05-03
BR112012009121A2 (pt) 2017-08-29
AU2016203817B2 (en) 2017-09-07
KR101813988B1 (ko) 2018-01-02
SI2490532T1 (sl) 2017-03-31
MX368459B (es) 2019-10-03
CY1118966T1 (el) 2018-01-10
AU2017272296A1 (en) 2018-01-25
EP2490532B1 (en) 2016-11-23
EP3143875A1 (en) 2017-03-22
ES2814178T3 (es) 2021-03-26
TW201116279A (en) 2011-05-16
RU2015147509A (ru) 2019-01-14

Similar Documents

Publication Publication Date Title
HRP20170236T1 (hr) Novi pripravci za sprječavanje i/ili liječenje degenerativnih poremećaja središnjeg živčanog sustava
IL241791A0 (en) Historical use of 3,1-diphenylprop-2-en-1-one for the treatment of liver disorders
GB201001047D0 (en) Methods and compositions for the treatment of neurological disorders
HK1168005A1 (zh) 用於預防和/或治療中樞神經系統退行性紊亂的方法
EP2170309A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
EP2552433A4 (en) COMPOSITIONS AND METHODS OF TREATING SOMATOSENSORY DISEASES
IL209032A0 (en) Compositions and methods for treating digestive disorders
EP2331088A4 (en) COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
EP2429530A4 (en) METHOD AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC ILLNESSES
GB2495885B (en) Combination pharmaceutical composition and methods of treating genitourinary system disorders
EP2550361A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDER
HK1205503A1 (zh) 新穎的化合物用作預防和/或治療溶酶體貯積失調和/或中樞神經系統的退化性失調
EP2475390A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF TYROSINE KINASE RECEPTOR MEDIATION DISEASES OR DISORDERS
HU0900231D0 (en) Compositions for the treatment of allergic disorders
EP2219650A4 (en) COMPOSITIONS AND METHODS FOR TREATING FIBROPROLIFERATIVE DISORDERS
EP2612668A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DEGENERATIVE NEUROLOGICAL CEREBRAL DISORDERS
EP2582832A4 (en) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CENTRAL ANIMAL NERVOUS SYSTEM FOR PSYCHIATRIC DISORDERS
MX2011013073A (es) Compuestos 1-(2-alquil-2,3-dihidro-benzofuran-4-il)-pirrolidin-3-i laminoacilo.
EP2370087A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF FLUID RETENTION DISORDERS
EP2578206A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISORDERS OF THE LOWER PART OF THE UROGENITAL SYSTEM
EP2255189A4 (en) COMPOSITIONS AND METHODS MODULATING THE G-PROTEIN SIGNALING FOR THE TREATMENT OF ASTHMA
GB0724947D0 (en) Composition for the treatment of psychiatric disorders
AU2007903760A0 (en) Composition and method for the treatment or prevention of spinal disorders